PHARMACIE DE GRASLA : revenue, balance sheet and financial ratios

PHARMACIE DE GRASLA is a French company founded 39 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in CHAUCHE (85140), this company of category PME shows in 2016 a revenue of 1.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE GRASLA (SIREN 338847031)
Indicator 2025 2024 2016 2015
Revenue N/C N/C 1 108 448 € 1 169 938 €
Net income 70 033 € 91 137 € 62 515 € 59 036 €
EBITDA N/C N/C 62 879 € 66 100 €
Net margin N/C N/C 5.6% 5.0%

Revenue and income statement

In 2025, PHARMACIE DE GRASLA generates positive net income of 70 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2025: 59 k€ -> 70 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

70 033 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 425%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 16%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

425.093%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

15.893%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1.1%

Solvency indicators evolution
PHARMACIE DE GRASLA

Sector positioning

Debt ratio
425.09 2025
2016
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Watch

In 2025, the debt ratio of PHARMACIE DE GRASLA (425.09) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
15.89% 2025
2016
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Watch

In 2025, the financial autonomy of PHARMACIE DE GRASLA (15.9%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Repayment capacity
6.2 years 2016
2016
Q1: 2.17 years
Med: 6.32 years
Q3: 11.13 years
Good

In 2016, the repayment capacity of PHARMACIE DE GRASLA (6.20) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 202.25. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

202.249

Liquidity indicators evolution
PHARMACIE DE GRASLA

Sector positioning

Liquidity ratio
202.25 2025
2016
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good -18 pts over 3 years

In 2025, the liquidity ratio of PHARMACIE DE GRASLA (202.25) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
6.52x 2016
2016
Q1: 4.69x
Med: 10.82x
Q3: 19.32x
Average

In 2016, the interest coverage of PHARMACIE DE GRASLA (6.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE GRASLA

Positioning of PHARMACIE DE GRASLA in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE DE GRASLA is estimated at 1 112 482 € (range 754 935€ - 1 745 638€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
754k€ 1112k€ 1745k€
1 112 482 € Range: 754 935€ - 1 745 638€
NAF 5 année 2025

Valuation method used

Net Income Multiple
70 033 € × 15.9x = 1 112 483 €
Range: 754 936€ - 1 745 638€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE GRASLA with other companies in the same sector:

Frequently asked questions about PHARMACIE DE GRASLA

What is the revenue of PHARMACIE DE GRASLA ?

The revenue of PHARMACIE DE GRASLA in 2016 is 1.1 M€.

Is PHARMACIE DE GRASLA profitable?

Yes, PHARMACIE DE GRASLA generated a net profit of 70 k€ in 2025.

Where is the headquarters of PHARMACIE DE GRASLA ?

The headquarters of PHARMACIE DE GRASLA is located in CHAUCHE (85140), in the department Vendee.

Where to find the tax return of PHARMACIE DE GRASLA ?

The tax return of PHARMACIE DE GRASLA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE GRASLA operate?

PHARMACIE DE GRASLA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.